Dendreon Corp., of Seattle, named Hans Bishop chief operating officer, effective Jan. 4, 2010.
Depomed Inc., of Menlo Park, Calif., promoted William Callahan to vice president of operations.
Dyadic International Inc., of Jupiter, Fla., named Michael J. Faby vice president of finance, effective Jan. 4, 2010.
EMD Serono Inc., of Geneva, an affiliate of Merck KGaA, named Howard Mayer chief medical officer.
Emisphere Technologies Inc., of Cedar Knolls, N.J., appointed Tim Rothwell to its board.
Enigma Diagnostics Ltd., of Oxford, UK, appointed Jorge Garces president and CEO of its U.S. team, with Greg Hamilton as chief operating officer and chief financial officer. Nick Williams was appointed chief financial officer in Europe, and Darren Hall was named chief operations officer in Europe.
EpiCept Corp., of Tarrytown, N.Y., appointed Bernard R. Tyrrell senior vice president of sales and marketing.
Formac Pharmaceuticals NV, of Leuven, Belgium, appointed Jan Rosier CEO, effective Jan. 1, 2010.
Genocea Biosciences, of Cambridge, Mass., appointed David Bernstein, Robert Coffman, Patrice Dubois and Peter Kiener to its scientific advisory board.
Genzyme Corp., of Cambridge, Mass., elected Robert J. Bertolini to its board.
Idera Pharmaceuticals Inc., of Cambridge, Mass., appointed Rahul Jasuja vice president of corporate development.
Immune Design Corp., of Seattle, named Bruce L. A. Carter executive chairman.
ImmunoCellular Therapeutics Ltd., of Los Angeles, appointed George Peoples, Constantine Ioannides and Cohava Gelber to its scientific advisory board.
ImmunoGen Inc., of Waltham, Mass., elected Howard Pien to its board. It also named Stephen C. McCluski chairman.
Jazz Pharmaceuticals Inc., of Palo Alto, Calif., appointed Kathyrn E. Falberg senior vice president and chief financial officer.
Ligand Discovery Inc., of Cambridge, Mass., appointed Errol B. De Souza executive chairman.
Light Sciences Oncology Inc., of Bellevue, Wash., elected Akbar Seddigh to its board.
MAP Pharmaceuticals Inc., of Mountain View, Calif., appointed Alan Petro vice president of manufacturing and technical operations.
Nektar Therapeutics Inc., of San Carlos, Calif., appointed Dennis Winger to its board and promoted Lorianne Masuoka to senior vice president and chief medical officer.
Neogen Corp., of Lansing, Mich., elected Richard T. Crowder to its board.
NeurogesX Inc., of San Mateo, Calif., appointed John A. Orwin to its board.
NormOxys Inc., of Cambridge, Mass., appointed David Clark chief medical officer.
Northwest Biotherapeutics Inc., of Bethesda, Md., named Robert A. Farmer to its board.
NovaDigm Therapeutics, of Grand Forks, N.D., named R. Gordon Douglas Jr. chairman.
Omeros Corp., of Seattle, elected Daniel K. Spiegelman to its board.
Oncolytics Biotech Inc., of Calgary, Alberta, appointed Alan Warrander senior vice president of global licensing and business development.
On-Q-ity, of Waltham, Mass., appointed Gary Palmer chief medical officer.
Opexa Therapeutics Inc., of The Woodlands, Texas, named Jaye Thompson head of Tovaxin clinical development. Dawn McGuire's role was expanded to acting chief medical officer.
Optimer Pharmaceuticals Inc., of San Diego, appointed Robert L. Zerbe to its board.
Orexigen Therapeutics Inc., of San Diego, appointed Dawn Viveash head of global regulatory affairs; Suzanne McDonald head of managed markets and government affairs; Preston Klassen head of global Contrave program; and Whedy Wang head of global biomedical information.
Oxford BioTherapeutics Ltd., of Oxford, UK, appointed Michael Moore nonexecutive chairman, named Jim Cornett chief operating officer of its U.S. operations and also appointed Jon Terrett vice president of oncology at its San Jose, Calif. facility.
Oxygen Biotherapeutics Inc., of Durham, N.C., added Ronald R. Blanck to its board.